Weight-loss drugs went from about 15% to as much as 28% average weight loss in a few years. Nicholas walks through retatrutide, tirzepatide, semaglutide and CagriSema, plus the caveats.
Read the full post: New developments in peptide research for weight loss and diabetes
In this episode
- 00:00 Cold open and intro
- 00:40 Retatrutide: phase 2 and TRIUMPH-2
- 01:06 Not approved, side effects and WADA
- 01:26 Tirzepatide beats semaglutide
- 01:37 Semaglutide: heart data, higher dose, the pill
- 01:51 Cagrilintide and CagriSema
- 02:07 Research vials and dosing math
- 02:26 Caveats and the takeaway
- 02:49 Wrap-up and Amino Club code
Peptides covered
Tools and deals
- Free reconstitution and dosing calculator: mypeps.info/calculator
- Amino Club: 40% off with code MYPEPSINFO at aminoclub.com
Sources
- https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
- https://www.nejm.org/doi/full/10.1056/NEJMoa2416394
- https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
- https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14725
- Full source list in the blog post.
Educational information only, not medical advice. Talk to a licensed clinician before starting, stopping or changing any medication. Research-grade peptides are not FDA-approved drugs.